Objective To explore the mechanism of the decreased expression of connexin gene (Cx) 43 in human gastric cancer. Methods Detections on mutation of Cx43 coding region in 30 cases of human gastric cancer and control normal tissues were undertaken by means of reverse transcription-polymerase chain reaction-single strand conformation polymorphism (RT-PCR-SSCP). Results [WTBZ]No point mutation of Cx43 was found in 30 cases with human gastric cancer. Conclusion The decreased expression of Cx43 was not related to the mutation of coding region, but to the non-coding sequence, especially the 5' regulation sequence. The results were helpful for the further studying of the relationship between gastric cancer and connexin gene. The RT-PCR-SSCP is effective, fast, inexpensive and radiationless for mutation detection, which may be a means of gene diagnosis for gastric cancer.

Objective NAG6, NAG 7 and BRD7 genes were novel tumor related genes identified recently. This study was designed to examine the expression of these genes in gastric cancer and matched paracancerous tissues and to investigate their roles in the occurrence and development of gastric carcinoma. Methods The expression levels of NAG6, NAG 7 and BRD7 in 34 cases of human gastric cancer and matched paracancerous tissues were analyzed by RT PCR, Northern blot analysis and Dot hybridization. Results The expression of NAG6 was absent in 61.8% gastric cancer tissues(21/34). The expression of NAG6 was significantly down regulated in gastric cancer tissues compared with that in paracancerous tissues ( P 0.05 ). The expression rates of NAG 7 in gastric cancer and paracancerous tissues were 88.2% (30/34) and 82.3% (28/34) respectively. BRD7 was expressed in all gastric cancers and matched paracancerous tissues. The results of RT PCR, Northern blot analysis and Dot hybridization all showed that the expressions of NAG 7 and BRD7 did not display any difference between gastric cancer and matched paracancerous tissues. Meanwhile, Dot hybridization also confirmed that NAG6 was significantly down expressed in gastric cancer. Conclusions NAG6 gene was significantly down regulated in gastric cancer tissues. The down regulation of this gene may play a key role in occurrence and development of gastric cancer, however it may be not associated with lymph node or distance metastasis. The expression levels of NAG 7 and BRD7 were not altered in gastric cancer. It seems that NAG 7 and BRD7 gene may not contribute to the occurrence and development of gastric carcinoma.

Objective To study the expression of connexin (Cx) genes and the effects of a variety of inducers on the expression changes of Cx and mutations of Cx coding sequences in human gastric cancer. Methods Northern Blot, RT PCR and PCR single strand conformational polymorphism were used. Results 1.There were regular expression patterns of Cx genes in human normal gastric epithelium, paracancerous tissues and gastric cancers. 2.RA and DMSO can induce the expression of Cx43 in gastric cancer and decrease of Cx46 expression by RA and TPA induction. 3.There was no any mutation in Cx43 coding sequences. Conclusion 1.Cx32 gene may be a specific gene in genome of gastric epithelium constructing gap junctional intercellular communication. 2.Cx43 is a inducible gene in gastric cancer cells. 3.The down regulation of Cx43 expression is not caused by mutation of Cx coding sequences in human gastric cancers. 4.The authors proposed a hypothesis on the variation of expression of Cx genes in human gastric cancer.

OBJECTIVE: To explore the role of nasopharyngeal carinoma associated gene 6 (NGX6) in Wnt/β-catenin signaling pathway and to identify whether there is feedback regulation between NGX6 and Wnt signal pathway once the Wnt signal is blocked. METHODS: pCMV-myc-NGX6 and pCMV-myc were transfected to colon cancer cell line SW62O and the expression of downstream target molecules of Wnt/β-catenin signaling pathway such as c-myc, cyclinD1, and c-jun were detected by Western blot. The eukaryotic expression vector pcDNA3.1 (+)-LEF1(DN) (without N-terminal β-catenin binding domain) was constructed to inhibit Wnt signaling pathway, and the effect was confirmed by Western blot and TCF-4 luciferase report system. The mRNA expression of NGX6 in SW620 was detected by RT-PCR after pcDNA3.1(+)-LEF1(DN) transient transfection. RESULTS: The expression of above molecules were obviously down-regulated by NGX6 transient transfection in SW620. The eukaryotic expression vector pcDNA3.1(+)-LEF1(DN) showed an inhibitory effect on Wnt/β-catenin signaling pathway. The mRNA expression of NGX6 in SW620 was up-regulated after pcDNA3.1(+)-LEF1(DN) transient transfection. CONCLUSION NGX6 could inhibit the expression of Wnt signaling downstream target genes, which maybe related to the potential feedback regulation between NGX6 and Wnt signal pathway.
Base Sequence ; Cell Line, Tumor ; Colonic Neoplasms ; genetics ; metabolism ; pathology ; Cyclin D1 ; genetics ; Down-Regulation ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Membrane Proteins ; genetics ; metabolism ; Molecular Sequence Data ; Proto-Oncogene Proteins c-myc ; genetics ; RNA, Messenger ; genetics ; metabolism ; Transfection ; Tumor Suppressor Proteins ; genetics ; metabolism ; Wnt Signaling Pathway ; genetics

Objective:To compare the efficacy of the combination of abidol, lopinavir/ritonavir plus recombinant interferon α-2b (rIFNα-2b) and the combination of lopinavir/ritonavir plus rIFNα-2b for patients with COVID-19 in Zhejiang province.Methods:A multicenter prospective study was carried out to compare the efficacy of triple combination antiviral therapy and dual combination antiviral therapy in 15 medical institutions of Zhejiang province during January 22 to February 16, 2020. All patients were treated with rIFNα-2b (5 million U, 2 times/d) aerosol inhalation, in addition 196 patients were treated with abidol (200 mg, 3 times/d) + lopinavir/ritonavir (2 tablets, 1 time/12 h) (triple combination group) and 41 patients were treated with lopinavir/ritonavir (2 tablets, 1 time/12 h) (dual combination group). The patients who received triple combination antiviral therapy were further divided into three subgroups: <48 h, 3-5 d and >5 d according the time from the symptom onset to medication starting. The therapeutic efficacy was compared between triple combination group and dual combination group, and compared among 3 subgroups of patients receiving triple combination antiviral therapy. SPSS 17.0 software was used to analyze the data.Results:The virus nucleic acid-negative conversion time in respiratory tract specimens was (12.2±4.7) d in the triple combination group, which was shorter than that in the dual combination group [(15.0±5.0) d] ( t=6.159, P<0.01). The length of hospital stay in the triple combination group [12.0 (9.0, 17.0) d] was also shorter than that in the dual combination group [15.0 (10.0, 18.0) d] ( H=2.073, P<0.05). Compared with the antiviral treatment which was started within after the symptom onset of in the triple combination group, the time from the symptom onset to the viral negative conversion was 13.0 (10.0, 17.0), 17.0 (13.0, 22.0) and 21.0 (18.0, 24.0) d in subgroups of 48 h, 3-5 d and >5 d, respectively ( Z=32.983, P<0.01), while the time from antiviral therapy to viral negative conversion was (11.8±3.9), (13.5±5.1) and (11.2±4.3) d, respectively( Z=6.722, P<0.05). Conclusions:The triple combination antiviral therapy of abidol, lopinavir/litonavir and rIFNα-2b shows shorter viral shedding time and shorter hospitalization time, compared with the dual combination antiviral therapy; and the earlier starting triple combination antiviral therapy will result in better antiviral efficacy.

Objective: Comparing the benefit of Abidor, lopinavir/ritonavir and recombinant interferon α-2b triple combination antiviral therapy and lopinavir/ritonavir and interferon dual combination antiviral therapy to hospitalized novel coronavirus pneumonia 2019 in Zhejiang province. Methods: A multi-center prospective study was carried out to compare the effect of triple combination antiviral therapy with dual combination antiviral therapy in 15 medical institutions of Zhejiang Province. All patients were treated with recombinant interferon α-2b (5 million U, 2 times/d) aerosol inhalation. 196 patients were treated with abidol (200 mg, 3 times/d) + lopinavir / ritonavir (2 tablets, 1 time/12 h) as the triple combination antiviral treatment group. 41 patients were treated with lopinavir / ritonavir (2 tablets, 1 time/12 h) as the dual combination antiviral treatment group. The patients who received triple combination antiviral therapy were divided into three groups: within 48 hours, 3-5 days and > 5 days after the symptom onset. To explore the therapeutic effects of triple combination antiviral drugs and dual combination antiviral drugs, as well as triple combination antiviral drugs with different antiviral initiate time. SPSS17.0 software was used to analyze the data. Results: The time of virus nucleic acid turning negative was (12.2 ± 4.7) days in the triple combination antiviral drug group, which was shorter than that in the dual combination antiviral drug group [(15.0 ± 5.0) days] (t = 6.159, P < 0.01 ). The length of hospital stay [12 (9, 17) d] in the triple combination antiviral drug group was also shorter than that in the dual combination antiviral drug group [15 (10, 18) d] (H = 2.073, P < 0.05). Comparing the antiviral treatment which was started within 48 hours, 3-5 days and > 5 days after the symptom onset of triple combination antiviral drug group, the time from the symptom onset to the negative of viral shedding was 13 (10,16.8), 17 (13,22) and 21 (18-24) days respectively (Z = 32.983, P < 0.01), and the time from antiviral therapy to the negative of viral shedding was (11.8±3.9) , (13.5±5.1) and (11.2±4.3) d. The differences among the three groups were statistically significant (Z=32.983 and 6.722, P<0.01 or<0.05). Conclusions The triple combination antiviral therapy of Abidor, Lopinavir/Litonavir and recombinant interferon α-2b showed shorter viral shedding time and hospitalization time compared with the dual combination antiviral therapy. The earlier the time to initiate triple antiviral treatment, the shorter the time of virus shedding.